PRELIMINARY RESULTS FROM AN OPEN‐LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMA. (June 2017) - Witzig, T.; Sokol, L.; Jacobsen, E.; Advani, R.; Mondejar, R.; Piris, M.; Burrows, F.; Melvin, C.; Mishra, V.; Scholz, C.; Gualberto, A.